As Gilead’s PD-1/TIGIT Trial Falls Short, Oncologists Say Better Biomarkers Needed

The ARC-7 trial showed a progression-free survival benefit in NSCLC, but the PFS benefit for zimberelimab/domvanalimab wasn’t as big as analysts and oncologists had hoped.